Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") is excited to announce publication of a preclinical ...

The deletion of two cancer genes, CHD1 and MAP3K7, improves how well tumours respond to cancer immunotherapy and could be used as biomarkers to help predict which patients are most likely to benefit ...

Pancreatic cancer is one of the most aggressive forms of cancer, often diagnosed later due the lack of symptoms in its early ...

Three Investigator-Initiated Trials (IITs) to utilize the Elephas Live™ Platform to evaluate the impact of a combination therapy of surgical intervention and immunotherapy MADISON, Wis., Feb. 23, 2026 ...

A new research paper was published in Volume 16 of Oncotarget on June 10, 2025, titled "Exceptional responders to immunotherapy in pancreatic cancer: A multi-institutional case series of a rare ...

Please provide your email address to receive an email when new articles are posted on . CHICAGO — A high-fiber diet intervention produced “promising” response results for patients receiving immune ...